Alzamend Neuro: A Glimpse Into The Evolution Of Non-Toxic Lithium Treatments

Alzamend Neuro is at the forefront of groundbreaking advancements in non-toxic lithium treatments showcasing the evolution of innovative solutions for various disorders. Although lithium has long been recognized as the go to treatment for episodes in Bipolar Disorder (“BD”), its effectiveness has been hindered by its therapeutic range and associated toxicity.

Through their pioneering work, Alzamend has developed AL001, a therapeutic compound of lithium, salicylate and proline leveraging co-crystallization, the unique drug delivery system licensed from the University of South Florida. This system offers a perspective on lithium therapy by reducing the toxic side effects commonly seen with currently available lithium salts. After recently completing a Phase IIA dose ranging study, Alzamend identified an optimal dosage for AL001 that ensures targeted delivery to the brain maximizing therapeutic benefits while minimizing overall exposure to the body. The goal of this dosage is to provide the maximum therapeutic window by remaining in the brain for periods of up to 48 to 72 hours instead of today’s treatment that only lasts up to 24 hours. These results pave the way for more effective approaches to lithium therapy and overcoming the current limitations associated with existing forms of lithium salts.

The Phase IIA Clinical Study

Alzamend has recently submitted an application to the U.S. FDA to begin the Phase IIA study of AL001, in patients with Bipolar Disorder commonly referred to by some as manic depressive disorder. This is a milestone step for Alzamend as they strive to revolutionize lithium therapy. The Phase IIA clinical study aims to explore the impact of AL001’s lithium levels in the brain compared to today’s lithium treatments for BD. This research builds upon studies conducted on mice, which suggest that lower doses of lithium from the AL001 compound can provide an overall greater therapeutic benefit to patients.

Lithium 2.0; The Potential of AL001

Alzamend is determined to replace the 300 mg TID dose of lithium carbonate with a 240 mg TID equivalent of AL001 resulting in a reduction of 20% in lithium dosage for patients. By refining how lithium is delivered into the brain, AL001 offers a future where regular therapeutic drug monitoring may not be necessary, bringing about changes for 7 million Americans living with BD and providing them with a more convenient and user-friendly treatment experience.

A Vision for the Future

Alzamend’s work with AL001 represents more than an advancement in lithium therapy; it signifies a leap to “Lithium 2.0”, the next-gen of lithium solutions featuring no toxicity and no requirement for medical monitoring.

CEO Stephan Jackman highlights the impact of developing a cutting-edge lithium product like AL001 emphasizing the Company’s commitment to advancing their pipeline, “Never in the history of mankind has there ever been a non-toxic lithium treatment for neurodegenerative or neuropsychiatric diseases or disorders…until now. Welcome to Alzamend Neuro!.”

The Broader Impact

Bipolar disorder is a mood disorder characterized by alternating periods of depression and abnormally elevated happiness. It affects around 3% of the U.S. population at some point in their lives. Alzamend’s unwavering dedication to advancing lithium therapy holds the promise to reduce the societal and individual costs associated with BD and enhance the quality of life for millions affected by BD and related disorders. This underscores their commitment to developing effective treatments.

Conclusion

Alzamend Neuro, Inc. Is leading the way in revolutionizing lithium therapy. The development of AL001 paves the way for a future where lithium treatment is not hindered by its toxicity making it more accessible and safer for patients. This ambitious endeavor offers hope in treating BD becoming a guiding light for millions and enabling a future where lithium can be widely embraced as the preferential  treatment option.

Disclaimer

It's important to note that this article is purely informational and should not be considered as advice or an endorsement of the company or its stock. The above details and conclusions are based on beliefs, expectations and are considered "forward looking statements." These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made.

More information including potential risk factors that could affect Alzamend’s business and financial results are included in Alzamend Neuro’s ALZN filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com.

If you have any queries regarding the Company or its therapeutic pipeline, please contact Alzamend Neuro, inc. via email at Info@Alzamend.com or, by calling 1 (844) 722-6333.

This post was authored by an external contributor and does not represent Benzinga's opinions and has not been edited for content. This contains sponsored content and is for informational purposes only and not intended to be investing advice.